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Novel plasma extraction procedure and
development of a specic enzyme-immunoassay of
oxytocin: application to clinical and biological
investigations of small cell carcinoma of the lung
C. PE´QUEUX, J .-C. HENDRICK, M.-T. HAGELSTEIN, V. GEENEN &
J.-J . LEGROS
University of Lie`ge, NeuroendocrineUnit, Pathology Institute, Lie`ge, Belgium
Pe´queux C, Hendrick J-C, Hagelstein M-T, Geenen V, Legros J-J. Novel plasma
extraction procedure and development of a specic enzyme-immunoassayof oxy-
tocin: application to clinical and biological investigations of small cell carcinoma
of the lung. Scand J Clin Lab Invest 2001; 61: 407–416.
Paraneoplastic secretion of the lactation-inducing hormone oxytocin (OT) has
been reported in about 30% of cases of small cell carcinoma of the lung (SCCL).
In order to investigate the role of OT in the biology of SCCL tumours, a specic
enzyme-immunoassay(EIA) for OT, which can be applied to both human plasma
and culture medium, has been developed. OT EIA is performed on 96-well micro-
titer plates coated with a rabbit polyclonal antibody (Ab) anti-OT (O4). This
antibody does not exhibit any signicant cross-reactivity either with vasopressin
(VP) or with vasotocin (VT). The immunological reaction involving Ab anti-OT
is a competition between the tracer (biotinylatedOT) and syntheticOT (standard
curve) or OT present in biological samples. In order to limit interference induced
by plasma proteins, plasma samples are ltrated by a one-step centrifugation on
centricon YM-3 (cut-oŒ 3000 Da). After plasma ltration, 90.7± 5.1 (SD) % (n=
22) immunoreactive (IR) OT is recovered. The sensitivity of OT EIA is 1 pmol/L,
while intra- and inter-assay coecients of variation (CV ) are around 3.41%
and 2.84%, respectively. In healthy volunteers, plasma IR OT is 7.28± 4.49
(SD) pmol/L (n= 32) with no gender diŒerence. As shown by the data both from
plasma of SCCL patients and from supernatants and cell contents of SCCL cell
lines, this EIA procedure oŒers a novel, reproducible, specic and sensitive
method for the measurement of IR OT.
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INTRODUCTION molecule including a peptide signal, the OT
peptide and the humanOT-associatedneurophy-
sin (OT-NP, 10 kDa). This OT precursor isOxytocin (OT) is a non-peptide hormone of
processed into OT and OT-NP. OT is specically1000 Da synthesized in magnocellular neurones
responsible for milk-ejection and OTÕ /Õ miceof the hypothalamic supraoptic and paraventric-
are unable to release milk in response to sucklingular nucleus under the control of a unique gene

















































408 C. Pe´queux et al.
in parturition by stimulating contraction of contents of SCCL-derived cell lines. This paper
describes the development of a specic enzyme-the uterine myometrium (oxytocic activity).
However, because of the redundancy of most immunoassay (EIA) based on the use of rabbit
anti-OT polyclonal antibodies (Ab) previouslybirth-controlling mechanisms, parturition nor-
mally occurs in OTÕ /Õ mice [3]. In addition, raised in our laboratory [23]. In addition, in this
work we report on a rapid and ecient pro-OT has been shown to cause luteolysis by stimu-
lation of endometrial prostaglandin secretion cedure for extraction of IR OT from human
plasma samples.[4], to participate in male reproductive physi-
ology [5] and to have a natriuretic eŒect through
an indirect action upon the heart [6 ]. Through
intrathymic OT expression and presentation by MATERIAL AND METHODS
proteins encoded in the major histocompatibility
Subjects and blood sampling
complex, it has also been proposed that OT is
implicated in the establishment of central T-cell Blood samples from 32 healthy donors (15
males, 17 females), included as control subjects,tolerance of the neurohypophysialfunctions and
in the control of T-cell development [7, 8]. OT and from 30 patients with SCCL at diŒerent
clinical stages were collected on heparinized oralso exerts a central inuence on reproductive
activities, and maternal, as well as aliative EDTA tubes. Male donors were aged between
25 and 61 years, and females between 24 and 54behaviour [9, for review see 10]. We have pre-
viously shown that OT is present in acetone years. Plasma was separated by centrifugation
at 2000 ´ g (for 10min at 4°C), then stored atextracts of small cell carcinoma of the lung
(SCCL), together with its associated OT-NP ± 20°C until assay. In addition to OT EIA,
VP radioimmunoassay (RIA, DPC Humbeek,[11]. High concentrations of OT and OT-NP
have been measured in plasma of about 30% of Belgium) was performed on these plasma
samples.SCCL [12, 13]. This type of lung cancer is
known to be associatedwith ectopic neuroendoc-
rine secretion of vasopressin (VP), the other
Reagents and cells
neurohypophysial hormone, which diŒers from
OT by two amino acids only. Other kinds of OT, VP, vasotocin (VT), bovine serum
albumin (BSA fraction V, A-4503), biotin-tumours secrete neurohypophysial hormones,
particularly breast cancer and thymic carcinoma aminocaproate N-hydroxysuccinimide ester
(B-3295), dimethyl-sulfoxide (DMSO), and[14–16, for a review see 17]. The incidence of

















,important in SCCL, and is often associated with
an elevation of VP-NP plasma levels [13]. The NaCl, KCl, glycerol, Tween 20 were obtained
from Merck (Germany). DPBS (17-513F),clinical expression of the VP ectopic secretion,
known as the Schwartz-Bartter syndrome [18], foetal calf serum (FCS ), RPMI 1640 were pur-
chased from Bio Whittaker (Belgium). Otherleads to water intoxication with hyponatremia,





(UCB, Belgium),endocrinal eŒects, several studies suggest that
VP exerts a mitogenic eŒect on tumour cell streptavidincoupledwith horseradishperoxidase
(HRP, RPN 4401, Amersham Pharmacia, UK),growth through a paracrine/autocrine type of
cell-to-cell signalling [19–21]. Until now, very goat anti-rabbit IgG (H-L goat no 401962,
Calbiochem, Germany), Dextran T70 (Pharm-little is known about the pathophysiological
consequences of OT synthesis and secretion by acia, Sweden) and [125I ]Tyr2-OT (NEN, USA).
DMS79, H146 and H345 (SCCL cell lines)SCCL on tumour development and patient sur-
vival. The primaryobjective of our investigations and Jurkat cells were purchased from American
Type Culture Collection (ATCC, USA).is to attempt to address that question [22]. In
order to investigate the biological role played by
OT in SCCL, we developed a specic and rapid
Cell-line cultures
method for the measurement of immunoreactive
(IR) OT in plasma samples of patients with Jurkat (106 cells/mL), DMS79 (106 cells/mL),
















































OT EIA with ltration applied to SCCL 409
cells/mL) cell lines were cultured in 12-well EIA with direct anti-OT Ab O4 coating
plates. Cells were incubated in RPMI 1640+ 10%
The 96-well microtiter plates (Nunc, Roskilde,
FCS (1mL), sometimes supplemented as rec-
Denmark) were coated overnight at 4°C with
ommended by the ATCC, in a humidied atmos-
anti-OT Ab O4 (200mL, 5 mg/mL) precipitated
phere with 5% CO
2
at 37°C. Supernatants and
with ammonium sulfate, as described above,
cells were separated every 24 h until 120h.
then dissolved in coating buŒer (0.lM NaHCO
3
,
Supernatants were directly frozen at ± 20°C,
pH 8.4). The plates were washed three times
while cells were lysed in 500mL deionized water
with washing buŒer (400mL, PO
4
3Õ 0.01M
and frozen at ± 20°C. OT EIA was then per-
pH 7.5+ 0.05% Tween 20). Subsequent washes
formed on supernatants and cell contents.
were performed in the same way (3 times with
400mL washing buŒer). Residual binding sites
were saturated for 2 h at room temperature with









, 2.7mM KCl ) supplemented
Initially, 23 antisera were obtained from 7
with BSA (1%). The following incubation steps
rabbits subcutaneously injected with OT conju-
were performed in assay buŒer (buŒer+ 0.5%
gated to thyroglobulin [23]. The anti-OT Ab,
BSA, 0.1% Tween 20). After washing, unknown
further named O4, used in the EIA procedure
plasma or standard OT (200mL, ranging from 1
with direct anti-OT Ab coating, was obtained
to 1000 pmol/L) was added, plates were incu-
from antiserum no 22. This antiserum, diluted
bated overnight at 4°C, and then washed. Tracer
at 1:10 000, shows a relative binding (B/Bo)
(200mL, biotinylated-OT, 1:10000) was added
of 42% when biotinylated-OT (1:10 000) is
for 30min at room temperature and then
displaced by 10 nM unbiotinylated-OT. The
washed. Streptavidin-HRP (200mL, 1:6000) was
dilution of antiserum no 22 could be increased
added for 30min at room temperature and after
to 1:150 000 when the EIA procedure with anti-
a nal wash, the plates were incubated for 15min
IgG Ab coating is used.
at room temperature with TMB solution
O4 was puried by precipitation with





ammonium sulfate: antiserum no 22 (1mL) was







(1mL) and shaken over-
reaction was stopped by the addition of H
2
SO
4night at 4°C. After three successive washes with







/phosphate buŒer, the pellet contain-
using an automatic reader at 450 versus 650nm.
ing O4 was dissolved in 1mL phosphate buŒer.
As measured by Bradford assay, this solution
EIA with anti-IgG coating [24]contained 25mg protein per mL.
The 96-well microtiterplates were coatedover-
night at 4°C with rabbit anti-IgG (200mL,
5 mg/mL) dissolved in coating buŒer. ResidualPreparation of biotinylatedOT
binding sites were saturated with buŒer sup-
OT was biotinylated according to Prakash plemented with BSA 1% (300mL) for 2 h at
et al. [24]. OT (1mL,1 mM) dissolved in phos- room temperature. The following incubation
phate buŒer (PO3Õ
4
0.05M, pH 7.5) was mixed steps were performed in assay buŒer. After
to biotinaminocaproate N-hydroxysuccinimide washing, unknown plasma or standard OT
ester (50mL, 220mmol/L) dissolved in DMSO. (200mL, ranging from 1 to 1000 pmol/L) was
After 30min incubation at room temperature, added simultaneously with anti-OT antiserum
biotinylated-OT was separated from unbound no 22 (100mL, 1:150000). The plates were incu-
OT by gel ltration on Sephadex G-25 bated overnight at 4°C. The procedure was
(Pharmacia, Sweden). Elution was performed ended as described above, using tracer, strep-





collected. The rst peak (biotinylated-OTconju-
gate) was identied by optic density (OD) at 260
OT plasma extraction by ltration
and 280nm and stored at ± 20°C after addition
of BSA (1%) and an equal volume of glycerol, Unknown plasma or hormone-free human
















































410 C. Pe´queux et al.
charcoal, 0.1% dextran T70 at 4°C) (1mL) was shows the denitive OT EIA standard curves
performed with the procedure of O4 coating andsubmitted to centrifugation (7500 ´ g, 4°C, 2 h)
on centricon YM-3 (cut-oŒ 3000 Da, Millipore, with synthetic OT diluted either in assay buŒer,
or in HFHP/YM-3, or in culture medium.USA) previously saturated with DPBS+BSA
0.1% (200mL). Only compounds with molecular
weight lower than 3000 Da (such as OT) can
Assay performance
pass through the lter.
For the assessment of the ltration, HFHP or As shown in Fig. 1D, anti-OT O4 Ab selected
in EIA is specic for OT and did not exhibitplasma (1mL) was supplemented with OT
(10mL) to obtain nal concentrations of from10 any cross-reactivity with either VP or VT at
concentrations up to 10nmol/L. The detectionto 500 pmol/L. After ltration on YM-3, OT of
ltrates was measured with the OT EIA. Assay limit (2 SD from zero) of the OT EIA was
1 pmol/L. The inter-assay and intra-assaybuŒer and seven plasmas (1mL) were sup-
plemented with [125I ]Tyr2-OT (100mL, 3.85 coecient of variation (CV ) has been deter-
mined, on standard curves, for three variousmCi/L, 1.8 nmol/L). After ltration on YM-3,
the radioactivity of each ltrate was measured OT concentrations, respectively 10 pmol/L,
100 pmol/L and 5000 pmol/L. The inter-assayon 100mL using an automatic gamma counter
(Perkin-Elmer, USA). CV was 1.83% for a sample B/Bo mean of
89.01± 1.63 (SD)% (n= 15), 2.02% for a sample
B/Bo mean of 65.30± 1.32 (SD) % (n= 15) and
4.68% for a sample B/Bo mean of 41.44± 1.94RESULTS
(SD) % (n= 15). The intra-assay CV was 3.15%
Standard curve
for a sample B/Bo mean of 87.4± 2.7 (SD) %
(n= 8), 3.11% for a sample B/Bo mean ofDiŒerent conditions were tested for the estab-
lishment of OT EIA standard curves, i.e. 1 to 68.1± 2.1 (SD)% (n= 8) and 3.97% for a sample
B/Bo mean of 40.5± 1.6 (SD)% (n= 8).1000 pmol/L of synthetic OT diluted in assay
buŒer, in charcoal-treated hormone-free human
plasma (HFHP) and in culture medium. As
YM-3 ltration
shown in Fig. 1A, EIA standard curves obtained
with direct O4 coating were similar and oŒer To assess centrifugation and ltration
eciency, OT was added to HFHP at variousmore sensitivity in assay buŒer and culture
medium than in HFHP. OD
450
fell from 3.3 and concentrations before ltration (Table I). The
mean of OT recovery was 89.4± 1.2 (SD)% (n=3.1 for OT diluted in assay buŒer and culture
medium, respectively,down to 2.0 for OT diluted 5). The same experiment was performed on two
plasma samples from SCCL patients (Table II ).in HFHP. Moreover, for the OT EIA standard
curve in HFHP, a positive cooperativity and/or Moreover, in this experiment, plasma centrifu-
gations were stopped after half the total time,protein-matrix eŒect was observed between 0
and 10 pmol/L OT. ltrates were collected, centrifugation was con-
tinued until the end of the ltration and ltratesSince these preliminary results strongly sug-
gested residual interferences from plasma pro- from the second part of the centrifugation were
collected. This test established the absence ofteins not eliminated by charcoal treatment,
HFHP was further ltrated on centricon YM-3 any signicant diŒerence between OT values
obtained from the ltrate collected at half-time(cut-oŒ 3000 Da). Synthetic OT (from 1 to
1000 pmol/L) was then added to ltrated HFHP centrifugation or ltrates collected at the end of
the centrifugation procedure. Indeed, the mean(HFHP/YM-3). As shown in Fig. 1A (anti-OT
O4 coating EIA), the standard curve in of OT recovery was 91.9± 3.1 (SD)% (n= 4) for
ltrates from the rst half-time ltration, andHFHP/YM-3 was very close to the one diluted
in assay buŒer and the sensitivity of OT EIA 89.1± 6.4 (SD)% (n= 4) for ltrates from the
second half-time ltration. Assay buŒer andwas improved. This absence of interference was
observed for both EIA procedures, but as shown seven plasma samples from patients were sup-
plemented with [125I ]Tyr2-OT (Table III ). Thein Fig. 1B, the sensitivity of OT EIA was also
enhanced when using direct O4 coating com- mean of [125I ]Tyr2-OT recovery after ltration
















































OT EIA with ltration applied to SCCL 411
Fig. 1. OT EIA standard curves. A. Comparison of standard curve sensitivity as a function of OD: in assay
buŒer (buŒer, j ), in hormone-free human plasma ltrated on centricon YM-3 (HFHP/YM-3, d ), in culture
medium (m ) and in hormone-free human plasma (HFHP, X). Assays were conducted with the procedure using
direct O4 coating. B. Comparison between standard curves obtained in assay buŒer (j , h ) and in hormone-free
human plasma ltrated on centricon YM-3 (HFHP/YM-3, d , s ), using the procedure with direct O4 coating
(j , d ) or with IgG coating (h , s ). Curves are plotted as a function of %B/Bo. C. Standard curves are plotted
as a function of %B/Bo and were conducted with the procedure using direct O4 coating in assay buŒer (buŒer,
j ), in hormone-free human plasma ltrated on centricon YM-3 (HFHP/YM-3, d ) and in culture medium (m).
All values are expressed as means± SD. D. Cross-reactivity of O4 with various neurohypohysial-related peptides:
OT (j ), VP (s ), VT (m). The assay was performed with the procedure using direct O4 coating.
value obtained in buŒer. The linearity of the
EIA was tested by measurements of OT in serial
dilutions (1:2, 1:5 and 1:10) of plasma from
Table I. YM-3 ltration assessment: oxytocin (OT)
three patients suŒering from SCCL (Table IV). recovery in hormone-free human plasma (HFHP).
OT concentrations were proportional at each
OT (pmol/L) added HFHP, OT recoverydilution, the mean of proportionality being
before ltration (pmol/L)
91.5± 6.8 (SD)% (n= 9). Moreover, similar stan-
dard curves were observed when OT was added 10 9 (90%)
50 44 (88%)to HFHP before or after YM-3 ltration (data
100 89 (89%)not shown). This ltration method allows up to
250 228 (91%)
90.7± 5.1 (SD)% (n= 22), considering the mean 500 445 (89%)
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Table II. YM-3 ltration assessment: oxytocin (OT) recovery in plasma with a stop at half-time of total ltration.
Plasma1, OT recovery (pmol/L) Plasma 2, OT recovery (pmol/L)
OT (pmol/L) added before ltration 1st half time 2nd half time 1st half time 2nd half time
0 8.4 8.2 7 7.5
200 185 (92.5) 160 (80) 175 (87.5) 180 (90)
500 471 (94.2) 455 (91) 466 (93.7) 476 (95.2)
Columns headed 1st half time show values of IR OT measured in ltrates collected after a half-time ltration.
Columns headed 2nd half time show values of IR OT measured in ltrates collected after the second half part of
ltration of the same initial plasma. Numbers in parentheses represent the percentage of OT recovery.
Table III. YM-3 ltration assessment: [125I ]Tyr2-OT patients D, J, K, L were situated between 12
recovery in plasma. and 12.5 pmol/L. The highest IR VP value
obtained in this study is 73 pmol/L (patient P).Recovery of
[125I ]Tyr2-OT ± SD (cpm)
IR OT concentration in culture medium and cellBuŒer 55 810 ± 815 (100)
Plasma 3 49 582 ± 442 (88.8) content of SCCL cell lines
Plasma 4 54 473 ± 273 (97.6)
IR OT was assayed in culture supernatants asPlasma 5 56 005 ± 898 (100.3)
Plasma 6 49 925 ± 419 (89.5) well as in cell contents of DMS79, H146 and
Plasma 7 49 848 ± 817 (89.3) H345 SCCL cell lines. As shown in Fig. 3, IR
Plasma 8 48 088 ± 642 (86.2)
OT concentrations stood in the same order of
Plasma 9 50 735 ± 306 (90.9)
magnitude in DMS79 and H146 cells. For these
Numbers in parentheses represent the percentage of two SCCL cell lines, the relative cellular fraction
[125I ]Tyr2-OT recovery in plasma, compared with was signicantly higher than the supernatant
buŒer.
fraction. Values of IR OT, obtained in super-
natants of these three cell lines, ranged from 5
to 40 pmol/L, demonstrating the existence of an
OT secretion by the SCCL cell lines studied.IR OT and VP concentrations in plasma of
control subjects and patientswith SCCL
Plasma IR OT concentration in control DISCUSSION
subjects was 7.28± 4.49 (SD) pmol/L (n= 32).
There was no signicant gender diŒerence: Our main objective was the development of a
6.78± 4.06 (SD) pmol/L for males (n= 15), and rapid and specic EIA for measurement of IR
7.73± 4.92 (SD) pmol/L for females (n= 17). OT in plasma, in culture media and in cell
From the 30 patients with SCCL, three groups contents of SCCL cell lines. The present OT
of patients could be distinguished on the basis EIA oŒers the advantageof being readily applied
of IR OT and VP plasma values: a group (n= to these conditions. The OT EIA detection limit
12, 40%) with elevated plasma IR OT concen- is 1 pmol/L, an order of magnitude very similar
trations (> 11.77 pmol/L, corresponding to the to other commercially available methods for
mean in control subjects+ SD); a group (n= 13, measurement of IR OT, moreover this limit is
43.3%) with elevated IR VP plasma concen- below the values observed in control subjects
trations (> 5 pmol/L, upper limit for normal VP 7.28± 4.49 (SD) pmol/L (n= 32). The inter- and
value used at the University Hospital (CHU) of intra-assay CVs are situated in a range lower
Lie`ge); and a group (n= 10, 33.3%) with normal than 5%, which ensures a good reproducibility
OT and VP plasma concentrations.Both IR OT and reliablility to the OT EIA. When directly
and VP plasma concentrations were elevated in applied to plasma, some interference by plasma
16.7% (n= 5) of SCCL cases (Fig. 2). A very proteins was suggested by the observation of a
high IR OT concentration of 980 pmol/L was positive cooperativity and/or protein-matrix
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Table IV. YM-3 ltration assessment: oxytocin (OT) recovery in diluted plasma.
Plasma 7, Plasma 10, Plasma 11,
Plasma dilutions before ltration OT (pmol/L) OT (pmol/L) OT (pmol/L)
1:1 980 74 45
1:2 500 (102) 31 (83.8) 19 (84.4)
1:5 196 (100) 13 (87.8) 7.9 (87.8)
1:10 96 (98) 6.7 (90.5) 4 (88.9)
Numbers in parentheses represent the OT proportionality (%) obtained after dilution compared to plasma
without dilution.
Fig. 2. IR OT (j ) and VP (s ) concentrations (pmol/L) in plasma of patients with SCCL. A. OT and VP
concentrations in patients with elevated OT plasma concentrations. B. OT and VP concentrations in patients with
elevated VP plasma concentrations.
Fig. 3. IR OT concentration in SCCL cells cultures. IR OT concentration was measured in supernatants (A)
and cell contents (B) of SCCL cell lines DMS 79, H146 and H345. The total OT production (C) was calculated
















































414 C. Pe´queux et al.
procedure was developed using a simple l- tration in supernatants (5 to 40 pmol/L) and cell
contents (25 to 155 pmol/L) of SCCL cell linestration of the plasma by centrifugation on
centricon YM-3. This plasma ltration is par- could even be measured early at the beginning
of the cultures, when they are low. This allowsticularly ecient and oŒers the advantage of
being easily performed in one step. The various us to demonstrate that OT could be secreted by
SCCL cell lines.experiments implemented to assess this ltration,
i.e. the addition of OT or [125I ]Tyr2-OT to In conclusion, this OT EIA using a stable
biotinylated-OT as a tracer and the associatedbuŒer, HFHP or plasma from SCCL patients,
allow us to estimate the mean of OT recovery plasmaltrationprocedureoŒers a reproducible,
specic and sensitive method that precludes theat 90.7± 5.1 (SD)% (n= 22). Moreover, this
recovery is homogenous during the all time usual time-consumingplasma extraction require-
ment. The measurement of elevated IR OTltration.This procedurealso precludes the time-
consuming drawback of the usual extractions concentrations in plasma of SCCL patients and
in supernatants and cell contents of SCCL cellrequiring several procedures such as elution with
organic solvent on the C
18
column, evaporation lines suggests that paraneoplastic secretion of
OT also occurs in this pathological condition.and lyophilization [25, 26]. Therefore, we con-
sider this ltration on YM-3 to be particularly Using this method, the aim of our future studies
will be to decipher the signicance of this para-simple and convenient in isolating a peptide such
as OT from interference by other plasma neoplastic secretion in the biology of SCCL
and other cancers.proteins.
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